OXiGENE Announces Third Quarter 2009 Earnings Conference Call and Webcast
November 03, 2009 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger
October 15, 2009 06:00 ET
|
Oxigene, Inc.
Acquisition to Add Approximately $33 Million in Cash to OXiGENE's Balance Sheet
Conference Call Today at 9:00 AM Eastern
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE,...
OXiGENE Announces Data Presentation At 2009 AACR-EORTC-NCI Conference
October 12, 2009 08:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., Oct. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases,...
Oxigene Announces Management Changes
October 08, 2009 08:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position
July 30, 2009 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., July 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces Second Quarter 2009 Earnings Conference Call and Webcast
July 24, 2009 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., July 24, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE Announces Closing of Registered Direct Offering
July 21, 2009 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., July 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company
developing novel therapeutics to treat cancer...
OXiGENE to Raise $10 Million in Registered Direct Offering
July 15, 2009 09:00 ET
|
Oxigene, Inc.
WALTHAM, Mass., July 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN)
(Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye...
OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology
July 06, 2009 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., July 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company
developing novel therapeutics to treat cancer and...
OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology
June 25, 2009 02:00 ET
|
Oxigene, Inc.
SOUTH SAN FRANCISCO, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a
clinical-stage biopharmaceutical company developing novel therapeutics to treat
cancer and eye diseases, announced that...